Non-Oncology Precision Medicine Market Size At Around US$ 150.2 Bn In 2030

The non-oncology precision medicine market would grow at a CAGR of 9.98% over the predicted time frame. The market is expected to increase in value from US$ 70.16 Bn in 2022 to US$ 150.2 Bn in 2030.

The on non-oncology precision medicine Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1798

Report Scope of the Non-Oncology Precision Medicine Market

Report Coverage	Details
Market Size by 2030	USD 150.2 Billion
Growth Rate from 2022 to 2030	CAGR of 9.98%
Largest Market	North America
Fastest Growing Region	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Product, Application, End-use, Ecosystem, Geography

A recent report provides crucial insights along with application based and forecast information in the Global Non-oncology precision medicine Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Non-oncology precision medicine market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Non-oncology precision medicine market are included as given below:

Non-oncology precision medicine Market Key Players

• Pfizer Inc.
• Qiagen Inc. 
• Quest Diagnostics Inc.
• Medtronic
• Novartis
• Laboratory Corporation of America Holdings 
• bioMérieux SA
• Abbott Laboratories
• F. Hoffmann-La Roche A 
• Eli Lilly & Company

Market Segments

 By Product Type

• Diagnostics
  • Genetic Tests
  • Biomarker Based Tests
  • Others
• Therapeutics

By Application

• Oncology
• CNS
• Immunology
• Respiratory
• Infectious Diseases
  • Respiratory Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections
  • Others
• Neurology
  • Neurodegenerative Disorders
  • Neuropsychiatric Disorders
  • Others
• Cardiovascular
  • Cardiac Myopathies and Arrhythmia
  • Others
• Lifestyle and Endocrinology
• Gastroenterology
• Others

By End-use

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

By Ecosystem

• Applied Sciences
  • Genomics
  • By Technology
    • Polymerase Chain Reaction (PCR)
    • Precision Medicine Next-Generation Sequencing (PM NGS)
    • Genome Editing
    • Other Technologies
  • Pharmacogenomics
  • Other Applied Sciences
• Precision Diagnostics
  • Molecular Diagnostics (MDx)
  • Medical Imaging
• Digital Health and Information Technology
  • Clinical Decision Support Systems (CDSS)
  • Big Data Analytics
  • IT Infrastructure
  • Genomics Informatics
  • In-Silico Informatics
  • Mobile Health
• Precision Therapeutics
  • Clinical Trials
  • Cell Therapy
  • Drug Discovery and Research
  • Gene Therapy

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Report Objectives

• To define, describe, and forecast the global non-oncology precision medicine market based on product, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
• To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
• To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the non-oncology precision medicine market

Table of Content

 Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Oncology Precision Medicine Market 

5.1. COVID-19 Landscape: Non-Oncology Precision Medicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Oncology Precision Medicine Market, By Product Type

8.1. Non-Oncology Precision Medicine Market, by Product Type, 2022-2030

8.1.1. Diagnostics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Therapeutics

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Non-Oncology Precision Medicine Market, By Application

9.1. Non-Oncology Precision Medicine Market, by Application e, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. CNS

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Immunology

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Respiratory

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Infectious Diseases

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Neurology

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Cardiovascular

9.1.7.1. Market Revenue and Forecast (2017-2030)

9.1.8. Lifestyle and Endocrinology

9.1.8.1. Market Revenue and Forecast (2017-2030)

9.1.9. Gastroenterology

9.1.9.1. Market Revenue and Forecast (2017-2030)

9.1.10. Others

9.1.10.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Non-Oncology Precision Medicine Market, By End-use 

10.1. Non-Oncology Precision Medicine Market, by End-use, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostic Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Research & Academic Institutes

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Non-Oncology Precision Medicine Market, By Ecosystem 

11.1. Non-Oncology Precision Medicine Market, by Ecosystem, 2022-2030

11.1.1. Applied Sciences

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Precision Diagnostics

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Digital Health and Information Technology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Precision Therapeutics

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Non-Oncology Precision Medicine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.3. Market Revenue and Forecast, by End-use (2017-2030)

12.1.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.6.3. Market Revenue and Forecast, by End-use (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.3. Market Revenue and Forecast, by End-use (2017-2030)

12.2.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.8.3. Market Revenue and Forecast, by End-use (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.3. Market Revenue and Forecast, by End-use (2017-2030)

12.3.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.8.3. Market Revenue and Forecast, by End-use (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.3. Market Revenue and Forecast, by End-use (2017-2030)

12.4.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.8.3. Market Revenue and Forecast, by End-use (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.6.3. Market Revenue and Forecast, by End-use (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Ecosystem (2017-2030)

Chapter 13. Company Profiles

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Qiagen Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Quest Diagnostics Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Medtronic

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Novartis

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Laboratory Corporation of America Holdings

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. bioMérieux SA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Abbott Laboratories

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. F. Hoffmann-La Roche A

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Eli Lilly & Company

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com